BioRestorative Therapies Management
Management criteria checks 2/4
BioRestorative Therapies' CEO is Lance Alstodt, appointed in Nov 2020, has a tenure of 3.5 years. total yearly compensation is $1.25M, comprised of 38.2% salary and 61.8% bonuses, including company stock and options. directly owns 2.54% of the company’s shares, worth $234.61K. The average tenure of the management team and the board of directors is 3.5 years and 5.6 years respectively.
Key information
Lance Alstodt
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 38.2% |
| CEO tenure | 3.5yrs |
| CEO ownership | 2.5% |
| Management average tenure | 3.5yrs |
| Board average tenure | 5.6yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$479k | -US$14m |
| Sep 30 2023 | n/a | n/a | -US$16m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$19m |
| Dec 31 2022 | US$452k | US$400k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$21m | US$275k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$19m |
| Dec 31 2020 | US$64k | US$64k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$7m |
| Jun 30 2020 | n/a | n/a | -US$11m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$350k | US$350k | -US$15m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$15m |
| Mar 31 2019 | n/a | n/a | -US$14m |
| Dec 31 2018 | US$750k | US$73k | -US$13m |
Compensation vs Market: Lance's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD663.90K).
Compensation vs Earnings: Lance's compensation has increased whilst the company is unprofitable.
CEO
Lance Alstodt (52 yo)
3.5yrs
Tenure
US$1,254,167
Compensation
Mr. Lance Alstodt serves as President, Chief Executive Officer and Chairman of the Board at BioRestorative Therapies, Inc. since November 16, 2020 and also served as Executive Vice President & Chief Strate...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 3.5yrs | US$1.25m | 2.54% $ 234.6k | |
| Chief Financial Officer | 2.5yrs | US$618.12k | 0.12% $ 10.9k | |
| Chief Scientist | 3.5yrs | US$1.19m | 2.48% $ 229.2k | |
| Vice President of Quality Assurance & Regulatory Compliance | 8.7yrs | US$287.85k | no data | |
| Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board | 6yrs | no data | no data |
3.5yrs
Average Tenure
53yo
Average Age
Experienced Management: BRTX's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 3.5yrs | US$1.25m | 2.54% $ 234.6k | |
| Chief Scientist | 3.5yrs | US$1.19m | 2.48% $ 229.2k | |
| Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board | 10.1yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 11.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.6yrs | no data | no data | |
| Independent Director | 2.5yrs | US$120.00k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$120.00k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$120.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.6yrs | no data | no data |
5.6yrs
Average Tenure
51yo
Average Age
Experienced Board: BRTX's board of directors are considered experienced (5.6 years average tenure).